Pyxis Oncology, Inc. (NASDAQ:PYXS) Financings

Pyxis Oncology, Inc.

Financings

RaiseDate
Public offering of common stock or pre-funded warrants with accompanying common warrants
Closed: US$110M raised · US$2.9 a share · Warrants at US$3.5 · Leerink Partners +2
Dealers: Leerink Partners (co-lead), Guggenheim Securities (co-lead), Wells Fargo Securities (co-lead)
Buyers: OrbiMed; GordonMD Global Investments; BVF Partners; Coastlands Capital; RTW Investments
Use of proceeds: Advance lead program MICVO through key clinical milestones including planned Phase 3 Headliner trial, plus working capital and general corporate purposes
Oct 2, 2026
Private placement of securities with accompanying warrants
Closed: US$50M raised
Use of proceeds: Advance MICVO through key clinical milestones and continue patient follow-up so data can mature
Aug 13, 2026
Private placement of common stock and warrants
Announced: about US$50M · US$2.551 a share · Warrants at US$3.289 · Wells Fargo Securities
Dealers: Wells Fargo Securities (lead)
Buyers: BVF Partners L.P. (led the financing); GordonMD Global Investments; RTW Investments; Coastlands Capital
Use of proceeds: Extend cash runway into Q2 2027 and advance lead clinical program MICVO through key clinical milestones
Jun 30, 2026

Read by 6ix AI from the company's releases